Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (71-80 of 228) with videos related to

Pageof 23
Sort By:
Life (Basel, Switzerland)|June 26, 2026
Characterization of HER2 Expression Levels, Including HER2-Ultralow, in a Retrospective Male Breast Cancer CohortMaximilian Marhold, Alexa Binder, Zsuzsanna Bago-Horvath, et al.
Annals of Surgical Oncology|July 12, 2011
Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patientsFlorian Fitzal, Martina Mittlboeck, Guenther Steger, et al.
Journal of Neuro-Oncology|July 21, 2016
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)Anna Sophie Berghoff, Gerda Ricken, Dorothee Wilhelm, et al.
Journal of Translational Medicine|December 17, 2013
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsBranka Petricevic, Johannes Laengle, Josef Singer, et al.
The Oncologist|June 30, 2012
Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancerMatthias Preusser, Gerhard Fülöp, Anna Sophie Berghoff, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 26, 2004
Zoledronate in a patient with pamidronate refractory hypercalcemia syndromeCatharina Wenzel, Rupert Bartsch, Dagmar Hussian, et al.
Histopathology|October 15, 2014
Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastasesAnna Sophie Berghoff, Gerda Ricken, Georg Widhalm, et al.
Clinical Journal of Oncology Nursing|March 19, 2016
A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access PortsChristoph Minichsdorfer, Thorsten Füreder, Bruno Mähr, et al.
Clinical Breast Cancer|July 2, 2013
Pertuzumab in breast cancer: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Wiener Klinische Wochenschrift|March 18, 2026
Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2- early breast cancerRupert Bartsch, Clemens Dormann, Daniel Egle, et al.
Pageof 23

Showing results (71-80 of 228) with videos related to

Sort By:
Pageof 23
Life (Basel, Switzerland)|June 26, 2026
Characterization of HER2 Expression Levels, Including HER2-Ultralow, in a Retrospective Male Breast Cancer CohortMaximilian Marhold, Alexa Binder, Zsuzsanna Bago-Horvath, et al.
Annals of Surgical Oncology|July 12, 2011
Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patientsFlorian Fitzal, Martina Mittlboeck, Guenther Steger, et al.
Journal of Neuro-Oncology|July 21, 2016
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)Anna Sophie Berghoff, Gerda Ricken, Dorothee Wilhelm, et al.
Journal of Translational Medicine|December 17, 2013
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsBranka Petricevic, Johannes Laengle, Josef Singer, et al.
The Oncologist|June 30, 2012
Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancerMatthias Preusser, Gerhard Fülöp, Anna Sophie Berghoff, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 26, 2004
Zoledronate in a patient with pamidronate refractory hypercalcemia syndromeCatharina Wenzel, Rupert Bartsch, Dagmar Hussian, et al.
Histopathology|October 15, 2014
Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastasesAnna Sophie Berghoff, Gerda Ricken, Georg Widhalm, et al.
Clinical Journal of Oncology Nursing|March 19, 2016
A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access PortsChristoph Minichsdorfer, Thorsten Füreder, Bruno Mähr, et al.
Clinical Breast Cancer|July 2, 2013
Pertuzumab in breast cancer: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Wiener Klinische Wochenschrift|March 18, 2026
Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2- early breast cancerRupert Bartsch, Clemens Dormann, Daniel Egle, et al.
Pageof 23